[Complete cytogenetic remission of chronic myeloid leukemia with low-dose interferon alfa-2b and monthly high-dose busulfan].
Two patients with chronic myelogenous leukaemia were treated according to an original regimen consisting of the association of alpha-2b interferon, three days a week, plus hydroxyurea during ten months, followed by interferon (same doses) and intermittent high doses of busulphan (50 mg, one dose per month, up to 6 doses). Both patients achieved minor cytogenetic remission in the first stage (50% and 80% of Ph'-positive metaphases, respectively). Upon concluding the second phase, one patient attained complete cytogenetic remission and the other showed major cytogenetic remission (3% Ph'-positive metaphases); complete remission was achieved in the second patient after 4 more doses of busulphan. Both patients remain in complete cytogenetic remission after 4 and 2 years, respectively, with three weekly doses of interferon as maintenance therapy. This protocol is quite different to others applied so far and might represent a good choice for patients unsuitable for bone marrow transplantation.